Neoadjuvant chemotherapy for stage II-III breast cancer: a single-center experience.

ABSTRACT:

Introduction

We conducted this study to reflect a single-center experience with the use of neoadjuvant systemic chemotherapy (NAC) for the management of women with operable breast cancer.

Methods

We conducted a retrospective chart review on all women presenting with operable, stage II-III, breast cancer and were scheduled for NAC at Suez Canal University Hospital. The primary outcome of this study was to estimate the proportion of patients with breast cancer who become eligible for breast-conserving surgery (BCS) after (NAC).

Results

A total of 147 patients were included. Before the initiation of chemotherapy, only 66 (44.9%) patients were indicated for (BCS). A total of 40 (49.4%) new patients, out of the 81 patients who were ineligible before chemotherapy, became el

SUBMITTER: Zaher HAE 

PROVIDER: S-EPMC10559473 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature